" />
Neuronal nuclear type 1 Ab:Titr:Pt:CSF:SemiQn: - CISMeF
Neuronal nuclear type 1 Ab:Titr:Pt:CSF:SemiQn:LOINC code
Preferred Label : Neuronal nuclear type 1 Ab:Titr:Pt:CSF:SemiQn:;
LOINC status : ACTIVE;
LOINC display name : Neuronal nuclear type 1 Ab (CSF) [Titer];
LOINC long common name : Neuronal nuclear type 1 Ab [Titer] in Cerebral spinal fluid;
LOINC short name : Hu1 Ab Titr CSF;
LOINC description : Anti-Neuronal Nuclear Antibody Type 1 Cerebrospinal fluid (CSF) titer. This antibody
recognizes a 35-40 kD component found in neuronal cell nuclei. ANNA-1 antibody is
found almost exclusively in patients with a history of tobacco use or passive exposure.
Women are affected twice as often as men. Cancer has been found in more than 90% of
seropositive patients. Small cell lung carcinoma (SCLC) has been found in 80% of patients.
A second malignant neoplasm is found in 13% of patients positive for ANNA-1 who have
SCLC. The most common clinical presentation of patients positive for ANNA-1 is peripheral
neuropathy, but they can exhibit any element of encephalomyeloradiculopathy. About
10% of patients present with gastroparesis or intestinal obstruction. ANNA-1 has also
been detected in children with intestinal dysmotility, cerbellar ataxia, and brainstem
encephalitis with and without neuroblastoma. It is detected in 5 to 10% of patients
with SCLC who do not have a paraneoplastic syndrome. Paraneoplastic syndromes are
autoantibody-mediated neurologic disorders associated with underlying tumors. These
syndromes arise when systemic tumors express antigens normally found only in neural
tissue. Serum is the preferred specimen. CSF results are sometimes positive when serum
results are negative. If a lumbar puncture is going to be performed as part of the
diagnostic workup, CSF testing is recommended to improve the detection rate. Information
from http://www.clinlabnavigator.com accessed 2008 15 02.;
Has component